The use of antiplatelet agents in patients with new
coronavirus infection exampled by acetylsalicylic acid
Larina V. N., Larin
V. G., Karpenko D. G., Varlamova Yu. Yu.
ABSTRACT
The outbreak of
the new coronavirus infection, which subsequently led to the pandemic,
negatively affected preventive and treatment measures in patients with acute
and chronic noncommunicable diseases, including
cardiovascular diseases (CVDs). Arterial hypertension, diabetes mellitus,
chronic kidney disease, coronary heart disease, obesity are the most prevalent
diseases in the structure of multimorbidity that
aggravate the outcomes in patients with COVID-19. Patients with COVID-19 and in
the absence of CVDs may develop cardiovascular complications, including
life-threatening ones. In addition, some therapeutic agents administered at the
beginning of the pandemic in experimental settings, such as antimalarial and
antiviral drugs, may cause cardiovascular adverse events. The severe course of
COVID-19 is accompanied by the development of
inflammatory alveolar lesions. Moreover, endothelial dysfunction also occurs,
which leads to microand macrothrombosis
in the blood vessels. Activation of thrombosis contributes to the development
of thrombotic/thromboembolic complications. Since activated platelets may
contribute to the pathogenesis of thrombotic complications, the feasibility of
using antiplatelets (acetylsalicylic acid, P2Y12
receptor blockers, dipyridamole) in COVID-19 is
currently being studied. The available clinical and scientific data
demonstrates the need for a comprehensive approach to the prevention and
treatment of new coronavirus infection, which should include viral replication
management, blocking the release of cytokines and other biologically active
substances, endothelial dysfunction, coagulation, fibrinolysis and, most
importantly, platelet function.
Keywords:
antiplatelet drugs, acetylsalicylic acid, COVID-19.
For citation:
Larina V. N., Larin
V. G., Karpenko D. G., Varlamova Yu. Yu. The use of
antiplatelet agents in a new coronavirus infection with the example of
acetylsalicylic acid. International Journal of Heart
and Vascular Diseases. 2023. 11(38):35-42. DOI:
10.24412/2311-1623-2023-38-43-51